First-in-Human Trial Shows Engineered Exosomes Safely Target KRAS G12D in Pancreatic Cancer
Key Insights
The iEXPLORE Phase I trial demonstrated that engineered exosomes carrying KRAS G12D (search)-specific siRNA (iExoKRASG12D (search)) were well-tolerated with no dose-limiting toxicities in 13 patients with advanced pancreatic ductal adenocarcinoma (search).
Treatment showed biological activity with evidence of target engagement, including reduced circulating tumor DNA levels and downregulation of phosphorylated ERK (search) in tumor biopsies.
Post-treatment biopsies revealed increased intratumoral CD8+ T cell infiltration and favorable remodeling of the tumor microenvironment, suggesting potential for combination immunotherapy strategies.
The iEXPLORE Phase I clinical trial has achieved a significant milestone in pancreatic cancer (search) treatment by demonstrating the safety and biological activity of engineered exosomes targeting the historically "undruggable" KRAS G12D (search) mutation. The study, conducted at MD Anderson Cancer Center, represents the first-in-human use of exosome-delivered siRNA therapy for pancreatic ductal adenocarcinoma (search) (PDAC (search)), a cancer with a median survival of less than 12 months despite combination chemotherapy.
Novel Therapeutic Approach Targets Critical Oncogene
More than 90% of PDAC (search) tumors harbor oncogenic KRAS (search) mutations, with KRAS G12D (search) found in approximately half of cases. The iExoKRASG12D (search) therapy utilizes exosomes derived from bone marrow mesenchymal stromal cells as natural delivery vehicles, electroporated with siRNA specifically targeting the KRAS G12D variant. This precision approach aims to selectively silence oncogenic KRAS, reduce downstream signaling, and remodel the tumor microenvironment.
Preclinical studies in mice and rhesus macaques established the safety profile and demonstrated preferential accumulation of the therapy in the pancreas and liver. Comprehensive toxicology evaluations showed no changes in body weight, liver or kidney function, or hematology parameters across multiple dose levels.
Phase I Trial Demonstrates Safety and Target Engagement
The clinical trial enrolled 13 evaluable patients with metastatic PDAC (search) harboring KRAS G12D (search) mutations who had progressed after at least one prior systemic therapy. The study consisted of two parts: a classical 3+3 dose-escalation (Phase Ia) enrolling 10 patients across three dose levels, and an accelerated titration design (Phase Ib) with three additional patients at higher doses.
No dose-limiting toxicities were observed at any dose level, and the maximum tolerated dose was not reached even at the highest tested dose of 4.8 mg siRNA per infusion. The highest cumulative dose administered was 28.8 mg of iExoKRASG12D (search) over 12 weeks. All patients tolerated the treatment well, with no treatment-related adverse events reported.
While no objective responses were observed, several patients achieved stable disease - a meaningful outcome in heavily pretreated metastatic PDAC (search). In Phase Ia, three patients achieved stable disease after three cycles, with one maintaining stability for up to six cycles before progression. In Phase Ib, all three patients showed stable disease during treatment before eventual progression.
Evidence of Biological Activity and Immune Activation
The trial provided compelling evidence of target engagement and biological activity. Circulating tumor DNA analysis revealed reduced KRAS G12D (search) mutant allele fraction in several patients after treatment, consistent with successful targeting of the oncogene. Post-treatment tumor biopsies from Phase Ib patients demonstrated downregulation of phosphorylated ERK (search), a key indicator of RAS pathway activity, along with a reduction in PanCK+ tumor cells.
Importantly, immunological analysis revealed increased intratumoral CD8+ T cell infiltration following treatment, suggesting favorable remodeling of the tumor immune microenvironment. This immune activation was accompanied by increases in CD4+ Foxp3+ regulatory T cells and CD4+ Foxp3- T cells, indicating a complex but potentially beneficial immunological response.
Preclinical Data Support Combination Strategies
Mechanistic studies revealed that KRAS G12D (search) suppression led to upregulation of Fas (search) expression on pancreatic cancer (search) cells through epigenetic remodeling. This included relief of KRAS G12D-mediated recruitment of DNA methyltransferase DNMT1 and histone methyltransferase EZH2 to the Fas promoter, enabling CD8+ T cell-mediated tumor cell elimination through Fas-FasL (search) interactions.
Building on these findings, preclinical combination studies demonstrated remarkable synergy between iExoKRASG12D (search) and anti-CTLA-4 therapy. The combination produced significant tumor regression, increased tertiary lymphoid structures, and robust survival benefits in mouse models. Notably, no such synergy was observed with anti-PD-1 therapy, suggesting specificity for CTLA-4 (search) blockade.
Studies using genetically modified mice confirmed that CD8+ T cells are essential for the anti-tumor effects of KRAS G12D (search) inhibition, while depletion of CD4+ T cells enhanced the therapeutic response, indicating that regulatory T cells may limit treatment efficacy.
Clinical Implications and Future Directions
The successful completion of this first-in-human trial establishes exosome-based siRNA delivery as a viable therapeutic platform for targeting previously undruggable oncogenes. The absence of toxicity, combined with clear evidence of target engagement and immune system activation, provides a strong foundation for advancing this approach.
The preclinical data strongly support the development of combination strategies, particularly with anti-CTLA-4 therapy. This combination approach could potentially overcome the historical resistance of pancreatic cancer (search) to checkpoint blockade immunotherapy by first priming the tumor microenvironment through KRAS (search) suppression.
The study enrolled patients with advanced disease who had exhausted standard treatment options, with time from diagnosis to death ranging from one to seven years. Despite this challenging patient population, the achievement of stable disease in multiple patients suggests meaningful biological activity that could translate to clinical benefit in earlier-stage disease or combination settings.
Advancing Precision Medicine in Pancreatic Cancer
This pioneering study represents a critical milestone in efforts to develop precision therapies for pancreatic cancer (search), one of the most treatment-resistant malignancies. The successful targeting of KRAS G12D (search) using engineered exosomes opens new possibilities for addressing other "undruggable" targets and provides a platform technology that could be adapted for various oncogenes.
The integration of sophisticated biomarker analyses, including circulating tumor DNA monitoring and comprehensive immune profiling, demonstrates the potential for developing personalized treatment approaches based on individual tumor characteristics and immune status. As the field moves toward Phase II trials, the combination of iExoKRASG12D (search) with immunotherapy represents a promising strategy for improving outcomes in this devastating disease.